Fresenius Kabi AG
www.fresenius-kabi.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fresenius Kabi AG
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Fresenius Divests Norwegian Plant To Prange
Fresenius Kabi has completed the divestment of a manufacturing plant in Halden, Norway, to Prange Group.
Fresenius Claims Edge With US Tocilizumab Biosimilar Approval
Fresenius Kabi has claimed an advantage in the biosimilar tocilizumab arena after its Tyenne rival to Actemra was approved by the US FDA in both intravenous and subcutaneous formulations.
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Medical Devices
- Infusion Therapy Equipment and Supplies
- Other Names / Subsidiaries
-
- mAbxience S.L.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice